the aid library

LIST OPTIONS

Filter

7845

Sort by:

Direction:

Download (1468)

View PDF (3416)

The Treatment of Diarrhoea

World Health Organization WHO (2005) C_WHO

A manual for physicians and other senior health workers. This fourth revision of the manual reflects recent clinical experience and research findings in diarrhoea case management. Compared to earlier versions, it includes revised guidelines on the management of children with acute diarrhoea using th... more

Download (1317)

View PDF (2275)

Immunization Essentials a practical Field Guide

USAID USAID (2004) CC

This guide provides a comprehensive overview of essential information related to immunization, including technical information about vaccines, a review of immunization program management best practices, guidance on the delivery of immunization services, monitoring and evaluation, disease surveillanc... more

Download (1731)

View PDF (2224)

Infection Control Assessment Tool for Primary Health Care Facilities

SIAPS USAID (2013) C1

Nosocomial or health-facility-acquired infections are a serious issue, representing one of the most significant causes of morbidity and mortality in healthcare systems and consuming many scarce resources, especially in developing countries. Although much has been done, particularly in the hospital s... more

Download (334)

View PDF (329)

Module: Psychoses

World Health Organization WHO (2015) C_WHO

Overview Learning objectives • Promote respect and dignity for people with psychoses. • Name common presentations of psychoses. • Name assessment principles of psychoses. • Name management principles of psychoses. • Perform an assessment for psychoses. • Use effective communicatio... more

Download (287)

View PDF (336)

Rwanda: HUMAN RESOURCES FOR HEALTH STRATEGIC PLAN 2011-2016

Ministry of Health, Rwanda (2011) C2

The purpose of this strategy is to guide the planning, management and development of human resources for health in Rwanda for the period 2011 - 2016. The overall aim of the plan is to increase the number of appropriately skilled, motivated and equitably distributed health service providers for Rwand... more

Download (91)

View PDF (146)

Belgian Antibiotic Policy Coordination Committee Policy paper for the 2014-2019 term

Erica Balligand, Michiel Costers and Evelyne Van Gastel Belgian Antibiotic Policy Coordination Committee (2014) C2

Antimicrobial resistance represents a big threat to public health. The Centers for Disease Control and Prevention (CDC) estimate that every year two million Americans are infected with a (multi-)drug resistant bacterium, resulting in 23,000 deaths. The WHO has repeatedly drawn attention to this majo... more

Download (135)

View PDF (193)

A WHO Guide to the Implementation of the WHO Multimodal Hand Hygiene Improvement Strategy

World Health Organization WHO (2009) C_WHO

Health care-associated infection (HCAI) places a serious disease burden and has a significant economic impact on patients and health-care systems throughout the world. Yet good hand hygiene, the simple task of cleaning hands at the right times and in the right way, can save lives. World Health O... more

Download (169)

View PDF (214)

Quality and safety practices for malaria rapid testing services

World Health Organization WHO (2022) C_WHO

This document is a guide defining requirements for quality and safety for malaria rapid diagnostic testing services to safeguard the quality of the results, the safety of the operators and patients and that of the environment for use by national malaria control programmes, regulators, implementers a... more

Download (126)

View PDF (150)

Eau, hygiène et assainissement, prévention et contrôle des infections dans les structures de traitement du choléra

UN Children's Fund UNICEF Groupe spécial mondial de lutte contre le Choléra (2019) C_UNICEF

Note technique. Les centres de traitement de choléra fournissent des soins hospitaliers aux patients atteints de choléra pendant les épidémies. Une prise en charge de qualité et l’isolement des patients atteints du choléra sont essentiels pour prévenir les décès et aider à lutter con... more

Download (74)

View PDF (118)

Health Services for Buruli Ulcer Control: Lessons from a Field Study in Ghana

Ackumey, M.M.; C. Kwakye-Maclean, E. O. Ampadu et al. PLoS Neglected Tropical Diseases (2011) CC

PLoS Negl Trop Dis 5(6): e1187. doi:10.1371/journal.pntd.0001187. Buruli ulcer (BU), caused by Mycobacterium ulcerans infection, is a debilitating disease of the skin and underlying tissue which starts as a painless nodule, oedema or plaque and could develop into painful and massive ulcers if left u... more

Download (82)

View PDF (324)

Chagas Clinical Research Platform

Drugs for Neglected Diseases Initiative DNDi Latin America (2022) CC

To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f... more

Download (94)

View PDF (267)

Human African Trypanosomiasis (HAT) - Sleeping Sickness

Drugs for Neglected Diseases initiative DNDi (2008) C2

At the forefront of DNDi’s efforts to develop new treatments is the need to understand the realities and treatment needs of patients and health care staff in the field. The ultimate goal for human African trypanosomiasis (HAT) is a truly simplified treatment which can be orally administered, impl... more

Download (131)

View PDF (700)

Schistosomiasis: Still a Cause of Significant Morbidity and Mortality

Verjeen, M. National Library of Medicine (2019) CC

Theodor Bilharz, a German professor of anatomy and chief of surgery at the Kasr El Ani Hospital of Cairo from 1850, first identified an infective organism, Distomum hematobium in 1851, which was renamed Schistosoma haematobium in 1858. It arose from a cestode worm, Hymenoleptis nana, lying in the sm... more

Download (114)

View PDF (151)

Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial

Pohlig G, Bernhard SC, Blum J, Burri C, Mpanya A, et al. PLOS Neclected Tropical Diseases (2016) CC

This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita... more

Download (68)

View PDF (410)

The Challenges of Conducting Clinical Research on Neglected Tropical Diseases in Remote Endemic Areas in Sudan

El-Safi, S.; Chappuis, F.; Boelaert, M. PLoS Neglected Tropical diseases (2016) CC

Most neglected tropical diseases (NTDs) occur in remote areas of low- and middle-income countries, where health systems are often poorly developed. Therefore, these neglected patients generally lack access to quality preventive, diagnostic, and therapeutic care [1]. The difficulty to access NTD-ende... more

Download (88)

View PDF (585)

National Guidelines on Nutrition Care, Support, and Treatment (NCST) for Adolescent and Adults. Second edition 2017

Ministry of Health Malawi (2017) CC

National Guidelines on Nutrition, Care, Support, and Treatment (NCST) for Adolescents and Adults These guidelines are intended to: • Establish a consistent set of nutrition interventions and recommendations aimed at managing and preventing undernutrition and overnutrition in adolescents and ad... more

Download (91)

View PDF (76)

Strengthening countries’ capacities to adopt and adapt evidence-based guidelines: a handbook for guideline contextualization

World Health Organization WHO (2023) C_WHO

Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev... more

Download (240)

View PDF (323)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (14)

View PDF (10)

A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes

Mitchell, S.; Malanda, B.; Damasceno, A. et al. World Heart Federation (2019) CC

In 2014, the World Heart Federation (WHF) launched an initiative to develop a series of Roadmaps [1e6]. Their aim is to identify potential roadblocks on the pathway to effective prevention, detection, and management of cardiovascular disease (CVD), along with evidence-based solutions to overcome... more

Download (25)

View PDF (17)

World Heart Federation Cholesterol Roadmap 2022

Ray, K.K.; Ference, B.A.; Séverin, T. et al. World Heart Federation (2022) CC

Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipopr... more